Articles by Jill Wechsler - Pharmaceutical Executive

ADVERTISEMENT

Articles by Jill Wechsler

Outrage Grows Over Drug Pricing

Nov 1, 2014

Insurers, physicians attack high-cost therapies in anticipation of specialty drug surge.

Ebola Crisis Challenges Pharma R&D

Oct 1, 2014

Companies gain support—and pressure—to deliver new treatments for spreading outbreak.

"Sunshine" Goes Live — Despite Incomplete Information

Oct 1, 2014

The federal Open Payments program has gone live, but biopharma companies continue to be concerned about the lack of context. Jill Wechsler reports.

Pharma Battles Hospitals Over Discount Pricing Program

Sep 3, 2014

Continued growth in a program that provides low-cost drugs to safety-net hospitals has sparked "trench warfare" over which medicines and providers are eligible for the discounts, writes Jill Wechsler.

Pharma Battles Hospitals Over 340B Pricing

Sep 1, 2014

Expansion of drug discount program ignites lawsuits, policy disputes.

Social Media Struggles Continue

Aug 1, 2014

Tweeting limited, corrections okay, says FDA, as industry, regulators wrestle with the digital world. Our Washington Correspondent Jill Wechsler reports.

Pre-emption and States' Rights

Jul 23, 2014

Pharma backs federal standards for compassionate use, drug importing, data transparency, and track-and-trace. Jill Wechsler reports.

What Price Innovation?

Jun 16, 2014

Payers are seeking clear assessment of drug value to rationalize high drug prices. This issue has moved to center stage due to mounting concern over the high price for Gilead's Sovaldi, writes Jill Wechsler.

Compassionate Use Requests Complicate Drug Development

Jun 1, 2014

Pharma, HCPs, and regulators walk tightrope in addressing early-access push while supporting biomedical R&D.

ADVERTISEMENT

Click here